Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Status:
Completed
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have
advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling
pathway that cancer cells need to grow and spread (metastasize).